XML 28 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6
BUSINESS SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2011
Concentration Risk [Line Items]  
Gross sales to three largest pharmaceutical wholesalers in the U.S. [Table Text Block]
 2011 2010 2009
McKesson Corporation26% 24% 25%
Cardinal Health, Inc.21% 21% 20%
AmerisourceBergen Corporation16% 16% 15%
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
                        Net Sales                        Property, Plant and Equipment
Dollars in Millions2011 2010 2009 2011 2010
United States$13,845 $12,613 $11,867 $3,032 $3,119
Europe 3,667  3,448  3,625  884  922
Japan, Asia Pacific and Canada 1,862  1,651  1,522  18  20
Latin America, Middle East and Africa 894  856  843  534  557
Emerging Markets 887  804  753  53  46
Other 89  112  198   -   -
Total$ 21,244 $ 19,484 $ 18,808 $ 4,521 $ 4,664
Net sales of key products [Text Block]
  Year Ended December 31,
Dollars in Millions2011 2010 2009
PLAVIX* (clopidogrel bisulfate)$7,087 $6,666 $6,146
AVAPRO*/AVALIDE* (irbesartan/irbesartan-hydrochlorothiazide) 952  1,176  1,283
ABILIFY* (aripiprazole) 2,758  2,565  2,592
REYATAZ (atazanavir sulfate) 1,569  1,479  1,401
SUSTIVA (efavirenz) Franchise 1,485  1,368  1,277
BARACLUDE (entecavir) 1,196  931  734
ERBITUX* (cetuximab) 691  662  683
SPRYCEL (dasatinib) 803  576  421
YERVOY (ipilimumab) 360   -   -
ORENCIA (abatacept) 917  733  602
NULOJIX (belatacept) 3   -   -
ONGLYZA/KOMBIGLYZE (saxagliptin/saxagliptin and metformin) 473  158  24
Mature Products and All Other 2,950  3,170  3,645
 Net Sales$ 21,244 $ 19,484 $ 18,808
Schedule of Segment Reporting Information [Table Text Block]
 Year Ended December 31,
Dollars in Millions2011 2010 2009
Capital expenditures$ 367 $ 424 $ 634
Depreciation  373   380   346
Reconciliation of segment income to earnings before income taxes [Text Block]
 Year Ended December 31,
Dollars in Millions2011 2010 2009
Segment income$5,083 $4,642 $4,492
         
Reconciling items:        
Provision for restructuring (116)  (113)  (136)
Impairment and loss on sale of manufacturing operations  -  (236)   -
Accelerated depreciation, asset impairment and other shutdown costs (75)  (113)  (115)
Process standardization implementation costs (29)  (35)  (110)
Gain on sale of product lines, businesses and assets 12   -  360
Litigation recovery/(charges) 22  19  (132)
Upfront, milestone and other licensing payments (187)  (132)  (347)
BMS Foundation funding initiative  -   -  (100)
Other (72)  (55)  (53)
Noncontrolling interest 2,343  2,094  1,743
Earnings from continuing operations before income taxes$ 6,981 $ 6,071 $ 5,602